Measurement and significance of antibodies against GM1 ganglioside Report of a workshop, 18 April 1989, Chicago, IL, U.S.A.
1989; Elsevier BV; Volume: 25; Issue: 2-3 Linguagem: Inglês
10.1016/0165-5728(89)90144-6
ISSN1872-8421
AutoresDonald M. Marcus, Norman Latov, B. P. Hsi, Baiba K. Gillard, Jack P. Antel, Stanley H. Appel, L. Callegaro, Genevieve Daune, Baiba K. Gillard, Norman Latoy, Donald M. Marcus, Eduardo Nobile‐Orazio, Alan Pestronk, Jacques Portoukalian, Richard H. Quarles, Edgar F. Salazar‐Grueso, Larry W. Schneider, Michael E. Shy, Andreas Steck,
Tópico(s)Galectins and Cancer Biology
ResumoTwelve laboratories from the United States, Canada, France, Italy and Switzerland participated in a workshop to compare assay used to measure anti-GM1 antibodies, and to discuss the clinical significance of these antibodies. A panel of test samples containing varying amounts of anti-GM1 antibody was prepared by mixing varied proportions of normal serum with a serum containing a monoclonal IgM antibody that bound GM1 ganglioside. Enzyme-linked immunosorbent assay (ELISA) data were supplied by eight laboratories and ten laboratories classified the sera as negative, weakly of strongly positive. Most laboratories correctly identified the two samples that contained the highest quantities of antibody, but there was considerable disagreement on the classification of the three samples with moderate or small
Referência(s)